OBIO · XBRL financial data

Orchestra BioMed Holdings financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	3,533	2,760	2,638	33,482
Cost of revenue	—	—	211	186	204	190
Research and development	—	—	21,945	33,822	42,804	58,185
Selling, general and administrative	—	—	14,034	20,258	23,931	26,914
General and administrative	—	275	2,960	—	—	—
Other operating income (expense)	—	—	(951)	2,386	3,277	(894)
Operating income (loss)	—	(395)	(3,080)	(51,506)	(64,301)	(51,807)
Interest income	—	16	345	—	—	—
Interest expense	—	—	1,300	1,400	297	—
Other income (expense)	—	—	—	—	(11)	—
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	—	(379)	(2,735)	(49,120)	(61,024)	(52,701)
Earnings per share, basic USD per share	—	(0.02)	(0.17)	(1.48)	(1.66)	(1.11)
Earnings per share, diluted USD per share	—	(0.02)	(0.17)	(1.48)	(1.66)	(1.11)
Weighted average shares, basic thousands of shares	—	20,450	16,426	33,225	36,821	47,747
Weighted average shares, diluted thousands of shares	—	20,450	16,426	33,225	36,821	47,747

Fiscal years (OBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,027	1,754	175	30,559	22,261	34,690
Marketable securities	—	—	63,915	56,968	44,551	71,822
Marketable securities, non-current	—	—	—	—	3,300	4,900
Accounts receivable	—	—	96	99	92	95
Inventory	—	—	276	146	173	310
Prepaid and other current assets	—	—	533	1,274	2,094	994
Total current assets	2,149	1,801	299	89,114	69,171	107,911
Property and equipment, net	—	—	1,489	1,279	1,384	1,715
Right-of-use asset	—	—	2,187	1,555	2,103	1,496
Total assets	162,156	161,824	68,076	95,212	76,173	114,857
Accounts payable	14	1	377	2,900	5,134	6,095
Accrued liabilities	105	14	1,367	5,149	6,084	9,890
Total current liabilities	119	166	1,744	11,208	16,207	16,736
Lease liability, non-current	—	—	1,683	1,038	1,687	936
Total liabilities	5,719	5,766	7,344	27,169	43,215	51,479
Accumulated deficit	(174)	(3,942)	(6,945)	(248,854)	(309,878)	(362,579)
Total stockholders' equity	(3,563)	(3,942)	(6,945)	—	—	—
Total liabilities and equity	162,156	161,824	68,076	95,212	76,173	114,857
Common shares outstanding (cover page) thousands of shares	20,450	20,450	11,212	35,777	38,313	58,521

Fiscal years (OBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	(379)	(2,735)	(49,120)	(61,024)	(52,701)
Stock-based compensation	—	—	3,375	7,625	10,615	11,978
Depreciation and amortization	—	—	222	287	308	327
Net cash from operating activities	—	(272)	(1,579)	(46,127)	(50,558)	(48,963)
Purchases of property and equipment	—	—	591	78	289	489
Net cash from investing activities	—	—	92,591	10,687	13,089	(26,941)
Repayments of long-term debt	—	—	6,446	10,849	—	—
Net cash from financing activities	—	—	(92,591)	46,215	29,171	88,333
Net change in cash	—	(272)	9,846	10,775	(8,298)	12,429

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026
InspireMD	15,149	1,771	(10,895)*	46.5M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Cytosorbents	4,413	9,633	(583)*	62.8M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.